IgA Nephropathy Clinical Trial
— ASSISTOfficial title:
A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)
The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).
Status | Recruiting |
Enrollment | 52 |
Est. completion date | October 1, 2025 |
Est. primary completion date | October 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects aged 18 and older at the time of signing the informed consent form (ICF) prior to initiation of any study specific activities/procedures. - Biopsy-proven IgA nephropathy. - Receiving a maximally tolerated and stable dose of RAS inhibitor therapy (ACEi or ARB) for at least 12 weeks prior to screening. Investigator discretion should be used in determining maximally tolerated and stable dose. - eGFR of at least 30 mL/min/1.73 m2 at screening based on the CKD-EPI equation. - Willing to agree to highly effective forms of contraception, as specified in the protocol, throughout the study and for up to 1 month afterward. In WOCBP, use of hormonal contraceptive agents must have been started at least 1 month prior to baseline. - Willing and able to provide informed consent and comply with all study requirements. - Inclusion Criteria for SGLT2i stable subjects - Receiving a stable dose of an SGLT2i for at least 8 weeks prior to screening - Must have a 24-hour urine protein of >0.5 grams/day. - Inclusion Criteria for Run-In Subjects - Must have a 24-hour total urine protein of >0.85 grams/day at screening - Willing to participate in an 8-week run-in period with an SGLT2i (per Investigator choice) - Additional Inclusion Criteria for Run-in Subjects at the end of Run-In - Must have completed the 8-week run-in period on a stable and well tolerated dose of an SGLT2i - Must have a 24-hour total urine protein of >0.5 grams/day confirmed at the Week -1 Visit - Must have an eGFR of = 30 mL/min/1.73 m2 based on the CKD-EPI equation at the Week -1 Visit - Receiving treatment with SGLT2i at a stable dose for at least 8 weeks prior to screening. Exclusion Criteria: - Current diagnosis with another chronic kidney disease, including diabetic kidney disease. - History of kidney transplantation or other organ transplantation. - Use of systemic immunosuppressant medications, such as steroids, for more than 2 weeks in the past 3 months. - Blood pressure above 150 mmHg systolic or 95 mmHg diastolic as evaluated by the Investigator. - Known history of heart failure or a previous hospital admission for fluid overload. - Clinically significant history of liver disease as assessed by the Investigator. - Hemoglobin below 9 g/dL as measured by the Investigator or prior history of blood transfusion for anemia within the past 3 months. - Malignancy within the past 5 years. Exceptions to this criteria include nonmelanoma skin cancer and curatively treated cervical carcinoma in situ. - For women, pregnancy, breast feeding, or intent to become pregnant during the study. and at least 1 month afterward. - For men, intent to father a child or donate sperm during the study. - Have received any investigational agent or approved treatment for IgAN (other than a RAS inhibitor) including SGLT2i (except for subjects in the SGLT2i stable stratum) within 1 month (or 5 half-lives of the agent, whichever is longer) prior to Screening. If the investigational agent is a cytotoxic or immunosuppressive agent then this washout period is 6 months. |
Country | Name | City | State |
---|---|---|---|
Australia | Monash Health- Monash Medical Centre | Clayton | Victoria |
Australia | The St. George Hospital | Kogarah | New South Wales |
Australia | Sunshine Hospital | St Albans | Victoria |
Australia | Prince of Wales Hospital | Sydney | New South Wales |
Spain | Hospital Torrecardenas | Almería | |
Spain | Hospital Ribera Polusa | Lugo | Galicia |
Spain | Hospital 12 de Octubre | Madrid | |
Spain | Hospital Universitario De Getafe (HUG) | Madrid | |
Spain | Hospital Virgen Macarena | Sevilla | |
United States | University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Nephrology Clinic | Birmingham | Alabama |
United States | University of North Carolina at Chapel Hill - Nephrology and Hypertension | Chapel Hill | North Carolina |
United States | NANI Research | Oak Brook | Illinois |
Lead Sponsor | Collaborator |
---|---|
Chinook Therapeutics, Inc. |
United States, Australia, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in proteinuria | The change in urine protein: creatinine ratio (UPCR) from baseline to Week 12 | Up to 12 weeks or approximately 3 months | |
Secondary | Change in proteinuria at 24 weeks of treatment | The change in UPCR from baseline to Week 24 | 24 weeks or approximately 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05016323 -
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
|
Phase 2 | |
Withdrawn |
NCT02433236 -
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT02231125 -
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
|
Phase 4 | |
Completed |
NCT01502579 -
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
|
N/A | |
Not yet recruiting |
NCT01203007 -
Diet Intervention in Food Sensitive Patients With IgA Nephropathy
|
N/A | |
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Completed |
NCT00657059 -
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
|
Phase 3 | |
Recruiting |
NCT04684745 -
Open-Label Extension Study of BION-1301 in IgA Nephropathy
|
Phase 2 | |
Completed |
NCT03719443 -
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT02052219 -
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
|
Phase 3 | |
Completed |
NCT02112838 -
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
|
Phase 2 | |
Completed |
NCT00767221 -
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
|
Phase 2 | |
Recruiting |
NCT04438603 -
The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Terminated |
NCT04905212 -
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
|
Phase 2 | |
Terminated |
NCT04042623 -
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT03633864 -
Fecal Microbiota Transplantation for Refractory IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT02954419 -
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
|
||
Recruiting |
NCT03001947 -
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
|
||
Completed |
NCT01224028 -
A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
|
Phase 2 |